Home > About LGC > Financial results > 2006-07 results

About LGC

Financial results

 

Financial highlights 2006-2007

LGC Group Holdings plc exceeded the milestone of being a £100m company, confirming its position as a successful and highly respected international group. Assisted by acquisitions, reaching £101m for the first time represents an increase of 18% on last year’s Group results of £85.9m.

International growth

The proportion of the Group's international turnover now stands at 28%, reflecting its strong base in Germany, France and elsewhere in Europe as well as with its joint venture in India.

Impact of UK forensic services market

Operating profit before exceptional items and EBITDA at £6.5m and £12.5m respectively are less than reported last year. Profitability for this year has been eroded in the forensics area of our business. Although LGC Forensics, which represents nearly 40% of Group turnover, experienced temporary disruptions in the UK forensic services market for police forces, there are major opportunities for profitable growth in the future. These include the expansion of forensic provision in other European countries such as in Germany where LGC has won new work and is building a reputation for the quality and speed of its forensic and paternity DNA results.

Highlights of the past year include:

  • LGC Forensics assistance in solving thousands of crimes. High profile forensic examinations led to successful convictions in the tragic murder of Damilola Taylor.
  • The launch of LGC Standards which brings together our reference materials distribution, proficiency testing, pharmaceutical reference materials production and analytical quality training, into a single division, with new sales offices in Hungary, Ireland and North America. Investment in our pharmaceutical reference materials production facilities in Luckenwalde, including an NMR system, has complemented pharmaceutical and chemical analytical capabilities at Runcorn.
  • The award of a new BSE testing contract in a continuation of our service to Defra in which LGC has tested in excess of 1.4 million brainstem samples since 2001.
  • The acquisition of a paternity testing business, Labor für Hämogenetik, based in Baden-Baden, Germany and the move of the Institut für Blutgruppenforschung LGC GmbH to the BIOcenter Technologiepark Köln, the largest science park in Cologne.
  • The launch of a gunshot discharge residues service using scanning electron microscope (SEM) technology to detect inorganic particles down to half a micron.
  • A memorandum of understanding to collaborate on reference materials and food analysis with the National Institute of Metrology, China.
  • An agreement to provide veterinary drugs testing for the Government of Malta.
  • Widespread recognition for our scientific capability under the UK Department for Innovation, Universities and Skills (DIUS) Chemical and Biological Measurement Programme. For example, LGC’s Dr Heidi Goenaga Infante, in collaboration with Simon Joel and his team at St Barts Hospital in London, published a paper in JAAS1 on the effects of combining selenium compounds with cytotoxic drugs in cancer therapy (also highlighted in Chemical Biology2 for progression in the field of organoselenium speciation analysis). References: (1) J. Anal. At. Spectrom., 2007, 22, 888. (2) Chemical Biology, 2 Aug 07, Issue 9, Research News.

 

Download Report and Accounts 2007 (347kb)